Comprehensive Metabolic Panel (CMP) Testing Market

Report Description
Table of Contents

Report Description

The global comprehensive metabolic panel (CMP) testing market size is estimated to be USD xx billion in 2021 and is expected to witness a CAGR of xx% during the forecast period. Growth in awareness concerning early diagnosis and treatment of diseases is a key driver for the growth of the global comprehensive metabolic panel (CMP) testing market. Additionally, rise in geriatric population base globally and increase in global cases of chronic diseases in the comprehensive metabolic panel (CMP) testing market are some of the other drivers propelling the market growth. Nevertheless, absence of skilled professionals to operate the testing panels and strict regulatory guidelines are expected to restrain the global market growth.

Global Comprehensive Metabolic Panel (CMP) Testing Market Size (USD Billion), 2021-2029

Source: Erevna Healthcare

By Disease Type

Based on disease type, the market is segmented into diabetes, kidney disease, liver disease, and others. In 2021, the kidney disease segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to the increase in prevalence of kidney disease and maximum application of analytes worldwide. Diabetes segment projected to grow at a profitable CAGR during the forecast period. This is attributed to the increasing cases of diabetes globally which is driving the comprehensive metabolic panel testing market.

By End User

Based on end user, the market is segmented into point of contact (PoC) and laboratories. In 2021, the laboratories segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to the easy accessibility, increasing market penetration, better usage worldwide. Point of contact (PoC) segment projected to grow at a profitable CAGR during the forecast period. This is attributed to the increasing demand from consumers for improved and efficient diagnosis, laboratory testing of CMP is expected to maintain the leading position in the market.

Regional Insights

In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the high disease liability, presence of major players in the region, increase in the share of healthcare expenditure in the per capita income, growth in initiatives from government, accessibility of technological advanced products in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the economic development in the region, growing government and corporate investment in healthcare sector, increasing travel tourism in the developing economies, and availability of skilled labour forces at economic costs, are the major factors in this region.

Competitor Insights

Some of the key players in the comprehensive metabolic panel (CMP) testing market are Abbott Laboratories (U.S.); Quest Diagnostics (U.S.); Laboratory Corporation of America Holdings (U.S.); Healthcare Limited (Australia); Unipath Lab (U.S.); Synlab Group (Germany); Abaxis Inc. (Zoetis) (U.S.); Tcg Corp. (U.S.); Scion Lab Services, LLC (U.S.); and Centogene (Germany). The leading players operating in the comprehensive metabolic panel (CMP) testing industry are adopting various strategies including R&D investments, adaption of advanced techniques, new technology launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The comprehensive metabolic panel (CMP) testing market report is categorized into the following segments and subsegments: